文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

超声内镜引导下胆囊引流术使用腔壁贴合金属支架作为恶性远端胆道梗阻的挽救治疗:一项大型多中心经验

EUS-guided gallbladder drainage using a lumen-apposing metal stent as rescue treatment for malignant distal biliary obstruction: a large multicenter experience.
PubMed 文献 · Gastrointest Endosc · 2023-06-29

这项多中心回顾性分析纳入14家意大利中心2015年6月至2020年6月连续48例因恶性远端胆道梗阻在ERCP和EUS引导下胆管十二指肠吻合术均失败后接受EUS引导下胆囊引流术放置腔壁贴合金属支架的患者,技术成功率100%,临床成功率81.3%,不良事件发生率10.4%。

要点

  • EUS引导下胆囊引流术放置腔壁贴合金属支架作为挽救治疗的技术成功率为100%。
  • 临床成功率为81.3%,2周后总胆红素平均下降66.5%。
  • 不良事件发生率为10.4%,其中2例轻度、3例中度(2例支架埋入)。

核心结论

  • EUS引导下胆囊引流术放置腔壁贴合金属支架作为恶性远端胆道梗阻的挽救治疗,在技术和临床成功率方面是有价值的选择,不良事件发生率可接受。
  • 据作者所知,这是关于该操作的最大样本研究。

研究设计与样本

  • 多中心回顾性分析,纳入2015年6月至2020年6月意大利14家中心连续接受EUS引导下胆囊引流术放置腔壁贴合金属支架作为恶性远端胆道梗阻挽救治疗的48例患者。
  • 主要终点为技术成功和临床成功,次要终点为不良事件发生率。

主要发现

  • 48例患者中女性占52.1%,平均年龄74.3±11.7岁。
  • 胆道狭窄病因包括胰腺腺癌85.4%、十二指肠腺癌2.1%、胆管癌4.2%、壶腹部癌2.1%、结肠癌4.2%和转移性乳腺癌2.1%。
  • 胆总管平均直径为13.3±2.8 mm,腔壁贴合金属支架经胃放置占58.3%、经十二指肠放置占41.7%。
  • 技术成功率为100%,临床成功率为81.3%,2周后总胆红素平均下降66.5%,平均手术时间26.4分钟,平均住院时间9.2±8.2天。
  • 5例患者(10.4%)发生不良事件:3例为术中不良事件,2例为迟发不良事件(发生于15天后);按美国胃肠内镜学会术语,2例为轻度、3例为中度(其中2例为支架埋入);平均随访122天。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: EUS-guided gallbladder drainage (EUS-GBD) with lumen-apposing metal stents (LAMSs) has been reported as a rescue treatment with encouraging results for the relief of jaundice in patients with distal malignant biliary obstruction (DMBO) and after failure of both ERCP and EUS-guided choledochoduodenostomy. METHODS: This was a multicenter retrospective analysis of all cases of consecutive EUS-GBD with LAMSs used as a rescue treatment for patients with DMBO in 14 Italian centers from June 2015 to June 2020. Primary endpoints were technical and clinical success, whereas the secondary endpoint was the adverse event (AE) rate. RESULTS: Forty-eight patients (52.1% women) with a mean age of 74.3 ± 11.7 years were included in the study. Biliary stricture was related to pancreatic adenocarcinoma (85.4%), duodenal adenocarcinoma (2.1%), cholangiocarcinoma (4.2%), ampullary cancer (2.1%), colon cancer (4.2%), and metastatic breast cancer (2.1%). The mean diameter of the common bile duct was 13.3 ± 2.8 mm. LAMSs were placed transgastrically in 58.3% of cases and transduodenally in 41.7%. Technical success was 100%, whereas clinical success was 81.3%, with a mean total bilirubin reduction after 2 weeks of 66.5%. The mean procedure time was 26.4 minutes, and the mean hospital stay was 9.2 ± 8.2 days. AEs occurred in 5 patients (10.4%): 3 were classified as intraprocedural and 2 were classified as delayed because they occurred after >15 days. When the American Society for Gastrointestinal Endoscopy lexicon was used, 2 AEs were mild and 3 were moderate (2 buried LAMSs). The mean follow-up was 122 days. CONCLUSIONS: Our study shows that EUS-GBD with LAMSs used as a rescue treatment for patients affected by DMBO represents a valuable option in terms of technical and clinical success rates, with an acceptable AE rate. To the best of our knowledge, this is the largest study concerning the use of this procedure. (Clinical trial registration number: NCT03903523.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Binda C, Anderloni A, Fugazza A, et al. EUS-guided gallbladder drainage using a lumen-apposing metal stent as rescue treatment for malignant distal biliary obstruction: a large multicenter experience. Gastrointest Endosc. 2023. PMID: 37392954. doi:10.1016/j.gie.2023.06.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。